Makovski, Victoria <br/><br/>
Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis.  [electronic resource] 

 -  International journal of cancer  Mar 2012 
 - 1420-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1097-0215 
<br/><br/><label>Standard No.: </label>10.1002/ijc.26139  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Cell Line, Tumor<br/>Cell Movement--drug effects<br/>Cell Proliferation--drug effects<br/>Cysteine--analogs & derivatives<br/>Farnesol--analogs & derivatives<br/>Lymphangioleiomyomatosis--drug therapy<br/>Lymphocytes, Null<br/>Mice<br/>Mice, Nude<br/>Monomeric GTP-Binding Proteins--antagonists & inhibitors<br/>Mutation--genetics<br/>Neuropeptides--antagonists & inhibitors<br/>Phosphorylation--drug effects<br/>Ras Homolog Enriched in Brain Protein<br/>Rats<br/>Ribosomal Protein S6 Kinases--metabolism<br/>Salicylates--pharmacology<br/>Tuberous Sclerosis Complex 2 Protein<br/>Tumor Suppressor Proteins--deficiency<br/>ras Proteins--genetics